Haney M, Foltin R W, Fischman M W
Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York State Psychiatric Institute, New York 10032, USA.
Psychopharmacology (Berl). 1998 May;137(1):15-24. doi: 10.1007/s002130050588.
Clinical evidence suggests that pergolide, a D1/D2 dopamine receptor agonist, may be useful in maintaining cocaine abstinence. We investigated pergolide's effects in a laboratory model of IV cocaine self-administration by humans. Twelve inpatient volunteers (7M, 5F), who reported spending an average of $170/week on cocaine, received pergolide (0.05 mg BID) for 8 days and placebo for 8 days, with drug order balanced across subjects. Self-administration sessions occurred on the last 4 days of maintenance on each medication. A modified seven-trial progressive ratio choice procedure (0, 8, 16, 32 mg/70 kg cocaine versus $5) was utilized, with sessions consisting of: (a) two sample trials, where participants responded to receive the dose and tokens available that day, and (b) five choice trials, where participants chose between the available dose and tokens. Following each trial, the response requirement for the chosen option increased by 400. Maintenance on pergolide 1) decreased cocaine-induced increases in ratings of "High," "Stimulated," cocaine "Potency," estimates of street value, and heart rate, 2) increased ratings of "I want cocaine," and 3) had no effect on cocaine self-administration. The increased desire to use cocaine during pergolide maintenance suggests that it has limited treatment utility at this dose, but given the attenuation of cocaine's subjective and cardiovascular effects, an investigation of a wider range of pergolide doses on cocaine self-administration and subjective effects is warranted.
临床证据表明，培高利特（一种D1/D2多巴胺受体激动剂）可能有助于维持可卡因戒断状态。我们在一个人类静脉注射可卡因自我给药的实验室模型中研究了培高利特的作用。12名住院志愿者（7名男性，5名女性），他们报告平均每周花费170美元购买可卡因，接受培高利特（0.05毫克，每日两次）治疗8天，然后接受8天的安慰剂治疗，药物顺序在受试者之间平衡。自我给药环节在每种药物维持治疗的最后4天进行。采用了改良的七次试验渐进比率选择程序（0、8、16、32毫克/70千克可卡因与5美元），试验环节包括：（a）两次样本试验，参与者通过反应来获得当天可用的剂量和代币；（b）五次选择试验，参与者在可用剂量和代币之间进行选择。每次试验后，所选选项的反应要求增加400。培高利特维持治疗1）降低了可卡因引起的“兴奋”“刺激”“可卡因效力”评分、街头价值估计以及心率的升高，2）增加了“我想要可卡因”的评分，3）对可卡因自我给药没有影响。在培高利特维持治疗期间使用可卡因的欲望增加，表明该剂量下其治疗效用有限，但鉴于可卡因的主观和心血管效应减弱，有必要对更广泛剂量范围的培高利特对可卡因自我给药和主观效应进行研究。
